Prostate And Other Male Cancers
Prostate cancer patients with a rapidly risking prostate-specific antigen (PSA) despite chemical or physical castration had lower rates of metastasis when treated with enzalutamide compared to those in a placebo group.
This relationship was bidirectional, with men who reported worse distress also subsequently reporting worse urinary, bowel, and sexual functions.
The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.
"We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC," said Michael Cookson, MD, member of the 2018 amendment panel.
In multivariable analysis, moderate white wine consumption increased the risk of prostate cancer (pooled risk ratio, 1.26; 95% confidence interval, 1.10 to 1.43; P=.001).
The Task Force recommends that for men 55 to 69 years of age, the decision to undergo prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one.
The estimated total cancer burden in PLWH will decrease from 8,150 cases in 2010 to 6,690 cases in 2030, with prostate and lung cancer projected to be the most common cancer types.
"These findings can help predict and guide successful surgical sperm retrieval in testes with testicular germ cell tumors," the authors write.
"Our results nominate mechanisms that operate across risk loci within disease phenotypes, suggesting new models for disease origins," the authors write.
At the 3-month follow-up, EX+D resulted in significantly greater improvements in mobility performance (P<0.02), muscular strength (P<0.01), body fat percentage (P<0.05), and fat mass (P<0.03), when controlling for baseline and androgen-deprivation therapy
The researchers observed a greater effect on PSA in the LOW arm versus the STD arm (mean log-change, −1.59 versus −1.19); according to predefined criteria, the noninferiority of LOW was established.
The 8-year rates of OS were 76 and 75% with 79.2 and 70.2 Gy, respectively (hazard ratio, 1.00; 95% confidence interval, 0.83 to 1.20; P=0.98). The 8-year cumulative rates of distant metastases were 4 and 6% for the 79.2- and 70.2-Gy arms, respectively (hazard ratio, 0.65; 95% confidence interval, 0.42 to 1.01; P=0.05).
Erleada is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer.
The researchers found that the median metastasis-free survival was 40.5 months in the apalutamide group and 16.2 months in the placebo group in the planned primary analysis performed after 378 events had occurred. Also significantly longer time to symptomatic progression was seen with apalutamide versus placebo.
The FDA approval was supported by results from the Phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled LATITUDE trial (N=1,199) which evaluated Zytiga 1000mg once daily in combination with prednisone 5mg once daily vs placebo in newly diagnosed, metastatic high-risk CSPC patients who had not received prior cytotoxic chemotherapy.
The researchers found that there were more obese patients in the high- versus low-/intermediate-risk group (41.2 versus 32.0%; P=0.006).
The researchers found that high adherence to a Mediterranean dietary pattern, rich in fruits and vegetables, fish, legumes, and olive oil, correlated with a lower risk of prostate cancer with a Gleason score greater than 6.
"Polygenic hazard scores can be used for personalized genetic risk estimates that can predict for age at onset of aggressive PCa," the authors write.
Within 4 months of enzalutamide initiation, four patients (1.1%) had at least one confirmed seizure; three additional patients (0.8%) experienced a seizure within four months following the 4-month study period.
Apalutamide, an investigational, next generation oral androgen receptor inhibitor, was assessed for safety and efficacy in the Phase 3 pivotal trial, ARN-509-003 (SPARTAN), which the NDA is based on.
Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).
As home genetic testing grows, patients will be bringing their results to physicians for reaction and response. Physicians will need to be proactively prepared.
Researchers of 2 newly published studies found that abiraterone (Zytiga) lowers risk of death by nearly 40% when added to standard androgen deprivation therapy.
In the per-protocol analysis, the researchers found that the average survival after surgery for those receiving capecitabine was 53 months, compared to 36 months for those who only had surgery. Existing Treatment Should be Considered Standard of Care in Biliary Cancer
For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.
The 2017 AUA list contains evidence-based recommendations to guide conversations between physicians and patients about what care is appropriate.
Nearly 7,000 Italian men participating in the Moli-sani epidemiological study aged ≥50 years were monitored for an average of 4.25 years.